Next phases of breast cancer drug research coming to RI

Via Peters

PROVIDENCE, R.I. (WPRI) — Advancements in a drug targeting breast cancer growth have oncologists hopeful about potential treatment options for patients with advanced forms of the disease. Results from the DESTINY-Breast04 Phase III trial showed the intravenous drug Enhertu, also known as trastuzumab deruxtecan, demonstrated “superior and clinically meaningful” progression-free and […]

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

Via Peters

This research complies with all relevant ethical regulations: The Sloane project, United Kingdom National Health Service Breast Screening Programme, was approved by the UK Health Research Authority (Ethical approval REF 08/S0703/147, 19/LO/0648); The Dutch DCIS cohort study, a Netherlands Cancer Registry (NCR; reference no 12.281), nationwide network and registry of […]

Time-Restricted Eating May Reduce CVD Risk After Breast Cancer

Via Peters

Time-restricted eating reduced cardiovascular risk among older breast cancer survivors, a single-group feasibility study suggests. The results show a 15% relative decline in cardiovascular risk, measured using the Framingham Risk Score, among at-risk breast cancer survivors (BCS) after only 8 weeks of following a time-restricted eating regimen, reported Amy A. Kirkham, PhD, […]

Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment

Via Peters

Emerging data with novel antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan-nxki (Enhertu), vic-trastuzumab duocarmazine, and disitamab vedotin (Aidixi) are showing encouraging activity in HER2-low breast cancer. Paolo Tarantino, MD, said this data suggests that the classification of HER2 should go beyond merely positive or negative. “In the future, we will […]

Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer

Via Peters

Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed. Three-year DFS was 88% with everolimus plus endocrine therapy and 89% with placebo plus endocrine therapy. Tolerability figured prominently in the results, as more than […]

Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer

Via Peters

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform optimized treatment decision-making, today announced 10,000 patients have been successfully enrolled in the FLEX Registry. Agendia’s unique FLEX Registry […]

ESR1 Mutations Provide Window Into Breast Cancer Metastasis

Via Peters

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined. Present in approximately two-thirds of estrogen receptor (ER)-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.1 “It is an important research area because it is […]

Global Breast Cancer Treatment Drugs Market Report, Growth Insight, Deep Research & Segment Analysis

Via Peters

Global “Breast Cancer Treatment Drugs Market” Reports 2022 provide key industry studies for Breast Cancer Treatment Drugs manufacturers with specific statistics, significance, definition, SWOT analysis, expert opinion and the latest developments in the world. The research report also covers market size, price, sales, revenue, market shares, gross margin, growth rate […]